Prelude Capital Management’s CTI BioPharma Corp. (DE) Common Stock CTIC Stock Holding History

Prelude Capital Management’s Portfolio CTIC Stock Details CTIC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-900	Closed	-$3K	–	1980
2017 Q3	$3K	Buy	+900	New	+$3.01K	﹤0.01%	1551
2017 Q2	–	Sell	-23,400	Closed	-$98K	–	2075
2017 Q1	$98K	Buy	23,400 +22,100	+1,700%	+$102K	0.01%	791
2016 Q4	$5K	Sell	1,300 -1,190	-48%	-$4.94K	﹤0.01%	1445
2016 Q3	$9K	Buy	2,490 +1,910	+329%	+$6.95K	﹤0.01%	1450
2016 Q2	$2K	Buy	+580	New	+$2.66K	﹤0.01%	1523
2015 Q4	–	Sell	-2,850	Closed	-$42K	–	1931
2015 Q3	$42K	Sell	2,850 -5,000	-64%	-$86.4K	0.01%	1104
2015 Q2	$153K	Buy	+7,850	New	+$152K	0.02%	737

Other funds holding CTIC

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

KCM

Kennedy Capital Management St Louis, Missouri $5.65B AUM 61.31% 1-Year Est. Return

OAM

Oxford Asset Management Oxford, United Kingdom $203M AUM 34.78% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Prelude Capital Management's CTIC Position: Q4 2017 in Review

Prelude Capital Management sold out of CTI BioPharma Corp. (DE) Common Stock (CTIC) in Q4 2017, closing a stake of 900 shares — an estimated $3K sold.

Prelude Capital Management first reported a position in CTIC in Q2 2015 and held it in 7 quarters. The position peaked at $153K in Q2 2015. 53 funds tracked by Wall St. Rank hold CTIC as of Q4 2017.

Prelude Capital Management reported no remaining CTI BioPharma Corp. (DE) Common Stock position as of Q4 2017 after selling out during the quarter.
Prelude Capital Management sold 900 CTI BioPharma Corp. (DE) Common Stock shares in Q4 2017, an estimated $3K.
Prelude Capital Management first reported a position in CTI BioPharma Corp. (DE) Common Stock in Q2 2015 and held it in 7 quarters.
Prelude Capital Management's CTI BioPharma Corp. (DE) Common Stock position peaked at $153K in Q2 2015.
53 funds tracked by Wall St. Rank held CTI BioPharma Corp. (DE) Common Stock as of Q4 2017.

Based on Prelude Capital Management's 13F filing for Q4 2017, filed 14 Feb 2018.